The objectives of the Protocol Review and Monitoring System (PRMS) are to implement a transdisciplinary scientific peer-review system that ensures internal oversight of the scientific quality and progress of clinical trials and optimally engages the institution's resources. The system ensures that clinical research trials at the USC Norris Comprehensive Cancer Center (NCCC) are of the highest scientific quality and integrity by review of the scientific merit, priorities and progress.
The specific aims of the PRMS are to: 1) maintain a Clinical Investigation Committee (CIC) with sufficient breadth of expertise to conduct an objective scientific and operational review of all clinical cancer research protocols;2) facilitate prompt initiation of approved protocols by interfacing with the IRB to ensure compliance with local and federal regulations;3) ensure and oversee a system of prioritization of clinical research protocols;4) monitor the scientific progress of clinical research protocols and ensure closure as required by interim analysis and stopping rules;5) terminate clinical research protocols that fail to meet expectations for scientific progress;6) review amendments for ongoing clinical research protocols;and 7) monitor compliance as well as gender and minority accrual in the conduct of clinical research protocols. The CIC is assisted by the Quality Assurance and Monitoring Committee (QAMC) in the monitoring of the progress of the studies. The QAMC fulfills multiple functions as detailed in the CISO section of the grant. In regards to PRMS, it provides the essential data regarding accrual and study conduct to the CIC, which allows the latter to perform its progress monitoring functions optimally.

Public Health Relevance

As mandated by the Cancer Center, the Clinical Investigations Support Office provides essential assistance and support to investigators through the CIC and through the QAMC in order to ensure scientific quality and integrity starting with the initiation of each study and continuing to study completion.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Southern California
Los Angeles
United States
Zip Code
Gopalakrishnan, R; Matta, H; Tolani, B et al. (2016) Immunomodulatory drugs target IKZF1-IRF4-MYC axis in primary effusion lymphoma in a cereblon-dependent manner and display synergistic cytotoxicity with BRD4 inhibitors. Oncogene 35:1797-810
Zeng, Chenjie; Matsuda, Koichi; Jia, Wei-Hua et al. (2016) Identification of Susceptibility Loci and Genes for Colorectal Cancer Risk. Gastroenterology 150:1633-45
Fanini, Francesca; Fabbri, Muller (2016) Cancer-derived exosomic microRNAs shape the immune system within the tumor microenvironment: State of the art. Semin Cell Dev Biol :
Cuellar-Partida, Gabriel; Lu, Yi; Dixon, Suzanne C et al. (2016) Assessing the genetic architecture of epithelial ovarian cancer histological subtypes. Hum Genet 135:741-56
Liu, Jie; Siegmund, Kimberly D (2016) An evaluation of processing methods for HumanMethylation450 BeadChip data. BMC Genomics 17:469
Taylor, Nicholas J; Thomas, Nancy E; Anton-Culver, Hoda et al. (2016) Nevus count associations with pigmentary phenotype, histopathological melanoma characteristics and survival from melanoma. Int J Cancer 139:1217-22
Pulido, Mario A; DerHartunian, Meleeneh Kazarian; Sehgal, Prerna et al. (2016) Data on isoaspartylation of neuronal ELAVL proteins. Data Brief 9:1052-1055
Pannunzio, Nicholas R; Lieber, Michael R (2016) RNA Polymerase Collision versus DNA Structural Distortion: Twists and Turns Can Cause Break Failure. Mol Cell 62:327-34
(2016) Identification of independent association signals and putative functional variants for breast cancer risk through fine-scale mapping of the 12p11 locus. Breast Cancer Res 18:64
Van Roosbroeck, Katrien; Fanini, Francesca; Setoyama, Tetsuro et al. (2016) Combining anti-miR-155 with chemotherapy for the treatment of lung cancers. Clin Cancer Res :

Showing the most recent 10 out of 635 publications